Overview

Myrcludex B vs Entecavir in Patients With HBeAg Negative Chronic Hepatitis B

Status:
Completed
Trial end date:
2014-10-04
Target enrollment:
Participant gender:
Summary
A randomized, open-label multicentre clinical trial of daily Myrcludex B versus entecavir in patients with HBeAg negative chronic hepatitis B.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Hepatera Ltd.
Treatments:
Entecavir